Hypercholesterolemia And Dyslipidemia

Question 1

Recommended first line therapy for lowering lipids and preventing CHD events in postmenopausal women.

Answer 1

Statin

Question 2

Most frequent risk factor for premature CHD

Answer 2

Low HDL-C

Question 3

Most effective and best tolerated agents for treating dyslipidemia.

Answer 3

Statins

Question 4

Major effect of Statin

Answer 4

Reduce LDL-C levels

Question 5

All statins have a t1/2 of

Answer 5

Atorvastatin rosuvastatin

Question 6

Statins taken as hydroxy acids and thus contraindicated with bile acid sequestrants.

Answer 6

Pravastatin and Fluvastatin

Question 7

Marketed in combination with amlodipine and used in treating patients with hypertension or angina as well as hypercholesterolemia.

Answer 7

Atorvastatin

Question 8

Reduces the clearance of Pitavastatin and raises blood concentrations.

Answer 8

Gemfibrozil

Question 9

Indicated for children >11 years

Answer 9

Atorvastatin
Lovastatin
Simvastatin

Question 10

Approved for children >8 years

Answer 10

Pravastatin

Question 11

Least likely to interfere with statin metabolism and the safest fibrate to use with statins.

Answer 11

Fenofibrate

Question 12

All statins are administered as B-hydroxy acid form except…. Which are administered as inactive lactones.

Answer 12

Simvastatin

Lovastatin

Question 13

All plasma statins and their metabolites are >95% protein bound except

Answer 13

Pravastatin 50%

Question 14

Major route of excretion for statins

Answer 14

Feces

Question 15

Major adverse effect of statin use

Answer 15

Myopathy

Question 16

Drug most commonly associated with statin induced myopathy

Answer 16

Gemfibrozil

Question 17

Statin that is not metabolized appreciably by the CYP system and is excreted unchanged in the urine

Answer 17

Pravastatin
Fluvastatin
Rosuvastatin

Question 18

Statin that can reduce venous thromboembolic events

Answer 18

Rosuvastatin

Question 19

Primary indication for B-andrenergic receptor antagonists

Answer 19

Angina

Question 20

B-blocker that promotes endothelial cell dependent vasodilation via NO pathway.

Answer 20

Nebivolol